Saturday November 17, 2018

New Therapy for Drug-Resistant Skin Cancer Suggested by Researchers

A team of researchers has managed to exploit a vulnerability in melanoma or skin cancer that develops resistance to a targeted therapy, providing a potential new therapeutic strategy to selectively kill the drug-resistant cancer cells.

0
//
The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said. (IANS)
Representational image, pixabay
Republish
Reprint

A team of researchers has managed to exploit a vulnerability in melanoma or skin cancer that develops resistance to a targeted therapy, providing a potential new therapeutic strategy to selectively kill the drug-resistant cancer cells.

The study has shown that when cancer cells develop drug resistance, they also acquire a new vulnerability, the Xinhua reported.

The researchers, led by Rene Bernards of the Netherlands Cancer Institute and Oncode Institute in Denmark, exposed this new vulnerability in melanoma that has developed resistance to treatment with a BRAF inhibitor — a targeted therapy that blocks a signalling pathway in the cancer cell through which it gets the message to keep on dividing.

Since more than half of all melanoma patients have a mutation in this BRAF gene, the BRAF-inhibitor stops tumour growth in those patients.

But within a few months, the tumour cell adapts the original signalling pathway and becomes active again, and even hyperactive.

The researchers, however, found that the hyperactive resistant melanoma cells produced large amounts of reactive oxygen species, but cancer cells still sensitive to the drug did not do so.

Combining the new compound with vitamin D allowed certain protective genes to be expressed at much higher levels than they are in diseased cells.
Representational image, pixabay

The study, published in the journal Cell, found that the abundance of free radicals caused the resistant melanoma cells to stop dividing, but they did not die.

When tested on mice along with an existing drug, vorinostat, which is known to stimulate the production of free oxygen radicals, the researchers saw tumours shrink under the influence of the drug, the report said.

This laid the foundation for a new therapeutic strategy: Treating patients with BRAF-mutated melanoma, as usual, with signal pathway inhibitors.

When the tumour becomes resistant, stop giving those inhibitors and immediately treat the patients with vorinostat to kill the resistant cancer cells.

Also Read: Leukemia Progression in Kids Can be Delayed Through Bone Density Treatment

“It is not a combination drug. It is very important that you first stop the signalling pathway inhibitors because they suppress the free radicals and thus eliminate the effects of vorinostat,” Bernards said. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

High Exposure to Radio Frequency Radiation Increase Risk of Cancer

Interestingly, the team found that rats exposed to whole body RFR lived longer than rats unexposed to any radiation

0
cancer
High exposure to radio frequency radiation linked to cancer. Pixabay

Exposure to high levels of radio frequency radiation (RFR) — used in 2G and 3G cell phones — can increase the risk of cancer tumours in the heart, brain and adrenal gland, researchers have warned.

The study, led by the US National Institutes of Health’s National Toxicology Programme (NTP), looked at the effects of exposing rodents to extremely high levels of radiofrequency throughout the entire body.

While high levels of RFR caused cancerous tumours in the heart (found very rarely in humans), brain and adrenal gland, of male rats, the findings on female rats were ambiguous.

“The exposures used in the studies cannot be compared directly to the exposure that humans experience when using a cell phone. In our studies, rats and mice received radio frequency radiation across their whole bodies,” John Bucher, researcher from the NTP, said in a statement.

“By contrast, people are mostly exposed in specific local tissues close to where they hold the phone,” Bucher added.

For the study, the team housed the animals in chambers specifically designed for the study.

Exposure to RFR began in the womb for rats and at 5 to 6 weeks old for mice, and continued for up to two years, or most of their natural lifetime.

Breast Cancer
Cancer ribbon. Pixabay

However, the RFR exposure was intermittent — 10 minutes on and 10 minutes off — totalling about nine hours each day.

In addition, the RFR levels ranged from 1.5-6 watts per kilogram in rats, and 2.5-10 watts per kilogram in mice.

“We believe that the link between radio frequency radiation and tumours in male rats is real,” Bucher noted.

Interestingly, the team found that rats exposed to whole body RFR lived longer than rats unexposed to any radiation.

“This may be explained by an observed decrease in chronic kidney problems that are often the cause of death in older rats,” the researchers noted.

Also Read- Actress Richa Chadha Speaks Upon Patriarchal Society

According to the US Food and Drug Administration (FDA), while animal studies contribute to discussions on the topic, “this study was not designed to test the safety of cell phone use in humans, so we cannot draw conclusions about the risks of cell phone use from it.”

Since the exposure levels and durations in the studies were greater than what people experience, “we agree that these findings should not be applied to human cell phone usage”, the FDA said on Thursday. (IANS)